Post your job infront of 100,000+ qualified LP's and GP's.
Chief Investment Officer CIO (Executive)
Recently Filled Jobs
Firms you might be interested in
Posted on: March 31, 2017, 10:36 a.m.
Dicerna Pharmaceuticals Inc, a maker of RNAi therapeutics, has secured $70 million in convertible preferred stock financing. Bain Capital Life Sciences was the lead investor. Other participants in the financing included EcoR1 Capital, Cormorant Asset Management, RA Capital, Domain Associates and Skyline Ventures. In conjunction with the funding, Dr. Adam M. Koppel, a managing director at Bain Capital Life Sciences, has been added to Dicerna’s board of directors. Full investment news articleRelevent to this post: Bain Capital Skyline Ventures,